Showing 2481-2490 of 3315 results for "".
- Atsena Therapeutics Initiates Part B of Phase 1/2 Clinical Trial Evaluating Gene Therapy ATSN-201 to Treat X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-initiates-part-b-of-phase-12-clinical-trial-evaluating-gene-therapy-atsn-201-to-treat-x-linked-retinoschisis/2482602/Atsena Therapeutics announced the initiation of Part B of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a gene therapy product candidate, leverages AAV.SPR, the company’s n
- Topcon Healthcare Appoints Christian Odaker as Chief Technology Officerhttps://modernod.com/news/topcon-healthcare-appoints-christian-odaker-as-chief-technology-officer/2482599/Topcon Healthcare announced the appointment of Christian Odaker, PhD, to the role of Chief Technology Officer (CTO). Dr. Odaker willsupport the company's 'Healthcare from the Eye' initiative, which leverages AI-powered disease detection and management using da
- National Eye Institute Study Revisits Role of Annexin-V Biomarker in Retinal Cell Degenerationhttps://modernod.com/news/national-eye-institute-study-revisits-role-of-annexin-v-biomarker-in-retinal-cell-degeneration/2482588/Recent findings from a National Eye Institute-led study shed new light on annexin-V, a widely used biomarker to track apoptosis and retinal cell death in eye disease. The study group identified that annexin-V also binds to immune cells, suggesting it may a have a role as a marker for ocular infla
- Atsena Completes Dosing in Part A of Phase 1/2 Trial Evaluating Gene Therapy to Treat X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-completes-dosing-in-part-a-of-phase-12-trial-evaluating-gene-therapy-atsn-201-to-treat-x-linked-retinoschisis/2482579/Atsena Therapeutics announced dosing has been completed in Part A of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a best-in-class gene therapy product candidate, leverages AAV.S
- Tenpoint and Visus Complete Mergerhttps://modernod.com/news/tenpoint-and-visus-complete-merger/2482576/Tenpoint Therapeutics and Visus Therapeutics announced the completion of their merger. “As we relaunch Tenpoint as a combined entity with Visus, we are excited to lead with a robust ophthalmology pipeline, starting with Brimochol PF, a near-term therapeutic medicine for presbyopia
- The Centre for Eye and Vision Research and SCOPE Health Partner to Innovate Ocular Surface Disease Solutionshttps://modernod.com/news/the-centre-for-eye-and-vision-research-and-scope-health-partner-to-innovate-ocular-surface-disease-solutions/2482571/The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have signed a Memorandum of Understanding (MoU) to collaborate on technologies to treat dry eye disease and other ocular surface conditions. The partnership aims to address unmet needs in eye care by leveraging SCOPE&rs
- UC Irvine Scientists Find DNA Damage is Key Factor in AMDhttps://modernod.com/news/uc-irvine-scientists-find-dna-damage-is-key-factor-in-amd/2482569/Accumulated DNA damage in the retina is a key contributor to age-related macular degeneration (AMD) and that targeting specific retinal cell types may lead to treatments that slow or stop progression, according to a research team co-led by the University of California, Irvine. The
- Ophthalmic Industry Veteran Scott Hunter Passes Awayhttps://modernod.com/news/ophthalmic-industry-veteran-scott-hunter-passes-away/2482564/Longtime ophthalmic industry leader Scott Hunter passed away on December 3, Neurotech announced. Mr. Hunter was the Chief Commercial Officer of Neurotech, a position he held since January 2023. “The entire Neurotech family mourns this loss. On behalf of the Board of Directors, man
- Nicole Skibinski Appointed Chief Executive Officer of Fluorescene Mediahttps://modernod.com/news/nicole-skibinski-appointed-chief-executive-officer-of-fluorescene-media/2482562/Nicole Skibinski was appointed Chief Executive Officer of Fluorescene Media, which aims to help optometry professionals connect, learn, and thrive. Ms. Skibinski has more than 20 years of leadership in the eye care and health care industries, with experience in
- Scientists Use Gene Editing to Treat Retinitis Pigmentosa in Micehttps://modernod.com/news/scientists-use-gene-editing-to-treat-retinitis-pigmentosa-in-mice/2482558/Researchers funded by the National Eye Institute (NEI) have successfully used a gene-editing technique to correct a mutation responsible for retinitis pigmentosa (RP). The study, led by Krzysztof Palczewski, PhD, of the University of California